🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06164314
Recruiting Not applicable

Perioperative Dexmedetomidine on Postoperative Delirium in Patients With Brain Tumors

NCT06164314 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Tiantan Hospital
Phase
Not applicable
Started
2024-01-25
Last updated
2025-02-17

Condition(s) studied

Postoperative Delirium

Investigational drug(s) / intervention(s)

Dexmedetomidine →

Dexmedetomidine: In Dex group, dexmedetomidine will continue to be used during and after surgery, with a infusion of 0.4ug/kg/ h from anesthesia induction to dural closure, and then 0.08ug/kg/ h to 48 hours postoperatively.In placebo group, equivalent normal saline will be injected during operation, and the intravenous analgesia pump will not contain dexmedetomidine after operation

Study summary

Neurosurgery is a risk factor for delirium. Dexmedetomidine might reduce delirium by reducing neuroinflammation, improving postoperative analgesia and sleep quality. The the primary hypothesis is that perioperative administration of dexmedetomidine can reduce the incidence of postoperative delirium

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with temporal glioma scheduled for a elective craniotomy * Age ≥18 years * Obtain written informed consent. Exclusion Criteria: * Patients with severe preoperative cognitive impairment * History of traumatic brain injury or previous neurosurgery * History of psychotropic medications * Allergy to dexmedetomidine * Pregnant or lactating women * History of obstructive sleep apnoea syndrome * Severe bradycardia(heart rate \<40 beats/min), sick sinus syndrome or second-to-third degree atrioventricular block * Severe hepatic dysfunction * Severe renal dysfunction

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing Tiantan Hospital Beijing China Recruiting

More Beijing Tiantan Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06164314 on ClinicalTrials.gov ↗ ← All trials in China